Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
14/08/2023
Kim Lauper1, Romain Aymon2, Denis Mongin2, Sytske Anne Bergstra3, Denis Choquette4, Catalin Codreanu5, Ori Elkayam6, Kimme Hyrich7, Florenzo Iannone8, Nevsun Inanc9, Lianne Kearsley-Fleet10, Tore K. kvien11, Eirik Kristianslund12, Burkhard Leeb13, Galina Lukina14, Dan Nordstrom15, Karel Pavelka16, Manuel Pombo-Suarez17, Ziga Rotar18, Maria José Santos19, Delphine Courvoisier20 and Axel Finckh21
ACR 2022
Lauper K, Aymon R, Mongin D, Bergstra S, Choquette D, Codreanu C, Elkayam O, Hyrich K, Iannone F, Inanc N, Kearsley-Fleet L, kvien T, Kristianslund E, Leeb B, Lukina G, Nordstrom D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos M, Courvoisier D, Finckh A. Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-treatment-discontinuation-due-to-adverse-events-and-the-effect-of-cardiovascular-risk-factors-or-type-of-jak-inhibitors-an-international-collaboration-of-registries-of-rheumatoid-arthr/
https://acrabstracts.org/abstract/evaluation-of-treatment-discontinuation-due-to-adverse-events-and-the-effect-of-cardiovascular-risk-factors-or-type-of-jak-inhibitors-an-international-collaboration-of-registries-of-rheumatoid-arthr/